IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion

PURPOSE: The first-in-human clinical trial with human bolus i.v. infusion IL-15 (rhIL-15) was limited by treatment-associated toxicity. Here, we report toxicity, immunomodulation, and clinical activity of rhIL-15 administered as a 10-day continuous intravenous infusion (CIV) to patients with cancers...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Conlon, Kevin C., Potter, E. Lake, Pittaluga, Stefania, Lee, Chyi-Chia Richard, Miljkovic, Milos D., Fleisher, Thomas A., Dubois, Sigrid, Bryant, Bonita R., Petrus, Michael N., Perera, Liyanage P., Hsu, Jennifer, Figg, William D., Peer, Cody J., Shih, Joanna H., Yovandich, Jason L., Creekmore, Stephen P., Roederer, Mario, Waldmann, Thomas A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697593/
https://ncbi.nlm.nih.gov/pubmed/31142503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3468
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados